Drug intelligence / Profile preview

Ex Vivo-Activated Lymph Node Lymphocytes

Development stage: Phase 1
Lead developer: National Cancer Institute
Modality: Cell Therapies
Administration: Intravenous

Overview

Ex Vivo-Activated Lymph Node Lymphocytes (X-ACT) is a cell therapy designed for the treatment of melanoma. It involves the extraction of a patient's own lymph node(s) located near a melanoma tumor. T cells from these lymph nodes are then activated and expanded outside the body (ex-vivo) using agents like anti-CD3/anti-CD28 microbeads and recombinant human interleukin-2. The activated T cells are subsequently injected back into the same patient intravenously with the aim of stimulating the patient's immune system to recognize and destroy melanoma cells.

Targets

pMHC (Melanoma-associated antigen peptide-MHC complex)

Beyond the preview

Go deeper on Ex Vivo-Activated Lymph Node Lymphocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ex Vivo-Activated Lymph Node Lymphocytes.

Explore the full profile